Key Patent Granted for ORAVEXX by United States Patent and Trademark Office
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORAVEXX™ Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Jun 30, 2025
Orcosa Appoints Kevin Kaplan, MD, as Chief Medical Officer
Apr 11, 2025
Orcosa Chosen to Present at BioNJ’s BioPartnering Conference 2025
Feb 05, 2024
Orcosa Comments on Positive Results from One-Year Follow-Up Study to NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™ for Acute Postoperative Pain
Jan 30, 2024
Orcosa Announces Two New Appointments to Board of Directors 
1 2 3 … 5 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2024 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement